Michael T. Campoli

Pryor Cashman client MDRNA, Inc., a leading RNAi-based drug discovery and development company, announced today the signing of a definitive agreement pursuant to which MDRNA will acquire Cequent Pharmaceuticals in an all stock transaction valued at approximately $46 million. The transaction includes certain loan provisions in addition to the acquisition provisions.  

The Pryor Cashman team handling the transaction for MDRNA includes partners Larry Remmel and Michael Dunworth, associates Michael Campoli and Cory Lamonica, and legal assistant Margaret Mitchell.